Houghton, P. J., Maris, J. M., Courtright, J., Friedman, H. S., Keir, S. T., Lock, R. B., … Smith, M. A. (2007). Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib. MOLECULAR CANCER THERAPEUTICS, 6(12), 3471S-3471S.

Houghton, Peter J., John M. Maris, Joshua Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, et al. “Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib.” MOLECULAR CANCER THERAPEUTICS 6, no. 12 (December 1, 2007): 3471S-3471S.

Houghton PJ, Maris JM, Courtright J, Friedman HS, Keir ST, Lock RB, et al. Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib. MOLECULAR CANCER THERAPEUTICS. 2007 Dec 1;6(12):3471S-3471S.

Houghton, Peter J., et al. “Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib.” MOLECULAR CANCER THERAPEUTICS, vol. 6, no. 12, AMER ASSOC CANCER RESEARCH, Dec. 2007, pp. 3471S-3471S.

Houghton PJ, Maris JM, Courtright J, Friedman HS, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Keshelava N, Reynolds CP, Morton CL, Smith MA. Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib. MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH; 2007 Dec 1;6(12):3471S-3471S.